A CORUÑA, Spain and SOUTH PLAINFIELD, N.J., May 03, 2017 (GLOBE NEWSWIRE) -- Today, Health in Code (HiC), (www.healthincode.com) a thought leader in the genetic cardiovascular field announced that it recently published in The Journal of the American College of Cardiology. The article titled, “Truncating FLNC Mutations Associated with High Risk Dilated and Arrhythmogenic Cardiomyopathies” demonstrates that truncating FLNC mutations are frequently complicated by sudden death and that the implantation of cardiac defibrillator should be considered in these patients. HiC was the first company to include the FLNC gene in its Next Generation Sequencing based cardiomyopathy panels four years ago and now includes it in its primary gene list. Admera Health (www.AdmeraHealth.com), an advanced molecular diagnostics company, has partnered with HiC to bring their clinical interpretation expertise to the United States.
Lorenzo Monserrat, MD PhD, CEO and Co-Founder/Scientific Director of HiC, stated, “This publication, a result of years of research and development, will undoubtedly produce a change in the clinical and genetic approach to cardiomyopathies. There is no question that the FLNC gene should be included systematically in genetic studies of young patients suspected of dilated, arrhythmogenic, and restrictive cardiomyopathies.”
“HiC’s genetic knowledgebase has allowed us to provide our patients and their physicians with actionable information, helping guide treatment decisions,” said Guanghui Hu, PhD, President and CEO of Admera Health. Dr. Hu continued, “The addition of the FLNC gene to the primary gene list to detect Dilated and Arrhythmogenic Cardiomyopathies in high risk patients will be an invaluable addition to those afflicted with cardio myopic diseases. This work demonstrates HiC’s commitment to making the CardioGxOne™ test and the corresponding report the market leader.”
Admera Health’s Cardiovascular test portfolio consists of three products. CardioGxOne™ is a 213-gene panel for diagnosis of inherited cardiovascular diseases and risk of sudden death. AtheroGxOne™ is an 84-gene panel for the risk assessment of inherited disease related to the development of atherosclerosis. Both tests were developed in collaboration with HiC. The third test in the portfolio is the PGxCardio™ test, a 15-gene pharmacogenomics panel to detect gene variants that can influence a patient’s response to cardiovascular drugs.
In addition to cardiovascular testing, Admera Health offers clinical testing for the risk assessment and diagnosis of pharmacogenomic drug interactions, cancer supportive therapy, and tumor profiling to guide selection of targeted therapies.
About Health in Code
Health in Code (HiC) is a company that is focused on the genetic diagnosis of inherited cardiovascular diseases, the interpretation of genetic results, and the development of databases and knowledge management systems to provide personalized medicine. HiC’s multidisciplinary team includes cardiologists, clinicians, informatics engineers, bioinformaticians, molecular biologists, pharmacologists, and documentalists.
About Admera Health
Admera Health is a CLIA-certified and CAP-accredited advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing, digital health, and providing research use only services. Research and development efforts are dedicated to developing cutting-edge diagnostics that span the continuum of care. Utilizing next generation technology platforms and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. It is Admera’s mission to deliver transformative, valuable solutions for patients, physicians, and clinical researchers. Admera health is committed to improving the health and well-being of the global community through the direct delivery of personalized, medically actionable results.
Admera Health Contact: Brady Millican, VP Business Development 908-222-0533 brady.millican@admerahealth.com
